Advertisement
Research Article| Volume 31, ISSUE 6, P495-502, November 2011

Download started.

Ok

Diuretics in the Treatment of Hypertension

  • Michael E. Ernst
    Correspondence
    Address reprint requests to Michael E. Ernst, PharmD, Department of Family Medicine, 01291-A/PFP, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242
    Affiliations
    Department of Pharmacy Practice and Science, College of Pharmacy, and Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA
    Search for articles by this author
  • Samuel J. Mann
    Affiliations
    Department of Medicine, Division of Nephrology and Hypertension, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY
    Search for articles by this author

      Summary

      Diuretics are powerful agents that impair sodium reabsorption in renal tubules. Their ability to alter long-term sodium balance induces important hemodynamic changes that result in a reduction in peripheral resistance and sustained reduction in blood pressure. A pharmacologically diverse group of drugs, they remain a mainstay in the therapy of hypertension. Clinical trials over the past 4 decades consistently have shown that blood pressure lowering obtained from a diuretic-based regimen reduces cardiovascular events. The ability of diuretics to augment the efficacy of nearly all other classes of antihypertensives makes them highly versatile and an important pharmacotherapeutic intervention to achieve blood pressure control. This article reviews key aspects of the use of diuretics relevant to the clinical management of hypertension.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grollman A.
        • Harrison T.R.
        • Mason M.F.
        • Baxter J.
        • Crampton J.
        • Reichsman F.
        Sodium restriction in the diet for hypertension.
        JAMA. 1945; 129: 533-537
        • Novello F.C.
        • Sprague J.M.
        Benzothiadiazine dioxides as novel diuretics.
        J Am Chem Soc. 1957; 79: 2028-2029
        • Moser M.
        • Macauley A.I.
        Chlorothiazide as an adjunct in the treatment of essential hypertension.
        Am J Cardiol. 1959; 3: 214-219
        • Ernst M.E.
        • Moser M.
        Use of diuretics in patients with hypertension.
        N Engl J Med. 2009; 361: 2153-2164
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • Goff D.C.
        • Murphy T.P.
        • Toto R.D.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment.
        Hypertension. 2008; 51: 1403-1419
        • Garg J.P.
        • Elliott W.J.
        • Folker A.
        • Izhar M.
        • Black H.R.
        Resistant hypertension revisited: a comparison of two university-based cohorts.
        Am J Hypertens. 2005; 18: 619-626
        • Beermann B.
        • Groschinsky-Grind M.
        Clinical pharmacokinetics of diuretics.
        Clin Pharmacokinet. 1980; 5: 221-245
        • Hughes A.D.
        How do thiazide and thiazide-like diuretics lower blood pressure?.
        J Ren Angio Aldo Sys. 2004; 5: 155-160
        • Nishizaka M.K.
        • Zaman M.A.
        • Calhoun D.A.
        Efficacy of low-dose spironolactone in subjects with resistant hypertension.
        Am J Hypertens. 2003; 16: 925-930
        • Saha C.
        • Eckert G.J.
        • Ambrosius W.T.
        • Chun T.Y.
        • Wagner M.A.
        • Zhao Q.
        • et al.
        Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
        Hypertension. 2005; 46: 481-487
        • Mach R.S.
        • Veyrat R.
        Clinical experiences with some of the newer diuretics, especially chlorthalidone.
        Ann N Y Acad Sci. 1960; 88: 841-863
        • Kakaviotos N.
        • Finnerty Jr, F.A.
        Comparison of chlorthalidone, a long-acting antihypertensive and diuretic agent, with chlorothiazide.
        Am J Cardiol. 1962; 10: 570-574
        • McLeod P.J.
        • Ogilvie R.I.
        • Ruedy J.
        Effects of large and small doses of hydrochlorothiazide in hypertensive patients.
        Clin Pharmacol Ther. 1970; 11: 733-739
        • Bengtsson C.
        • Johnsson G.
        • Sannerstedt R.
        • Werko L.
        Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate.
        BMJ. 1975; 1: 197-199
        • Carney S.
        • Gillies A.I.
        • Morgan T.
        Optimal dose of a thiazide diuretic.
        Med J Aust. 1976; 2: 692-693
        • Materson B.J.
        • Oster J.R.
        • Michael U.F.
        • Boltonn S.M.
        • Burton Z.C.
        • Stambaugh J.E.
        • et al.
        Dose response to chlorthalidone in patients with mild hypertension.
        Clin Pharmacol Ther. 1978; 24: 192-198
        • Cushman W.C.
        • Khatri I.
        • Materson B.J.
        • Reda D.J.
        • Freis E.D.
        • Goldstein G.
        • et al.
        Treatment of hypertension in the elderly.
        Arch Intern Med. 1991; 151: 1954-1960
        • Taler S.J.
        • Textor S.C.
        • Augustine J.E.
        Resistant hypertension.
        Hypertension. 2002; 39: 982-988
        • Gums J.G.
        • Lopez L.M.
        • Quay G.P.
        • Stein G.H.
        • McCarley D.L.
        Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension.
        Drug Intell Clin Pharm. 1988; 22: 680-684
        • Johnson J.A.
        • Gong Y.
        • Bailey K.R.
        • Cooper-DeHoff R.M.
        • Chapman A.B.
        • Turner S.T.
        • et al.
        Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
        Clin Pharmacol Ther. 2009; 86: 533-539
        • Wright J.M.
        • Musini V.M.
        First-line drugs for hypertension.
        Cochrane Database Syst Rev. 2009; 3 (CD001841)
        • Turnbull F.
        • Blood Pressure Lowering Treatment Trialists' Collaboration
        Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials.
        Lancet. 2003; 362: 1527-1535
        • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
        Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        JAMA. 2002; 288: 2981-2997
        • Wright J.T.
        • Probstfield J.L.
        • Cushman W.C.
        • Pressel S.L.
        • Cutler J.A.
        • Davis B.R.
        • et al.
        • ALLHAT Collaborative Research Group
        ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
        Arch Intern Med. 2009; 169: 832-842
        • Wright Jr, J.T.
        • Harris-Haywood S.
        • Pressel S.
        • Barzilay J.
        • Baimbridge C.
        • Bareis C.J.
        • et al.
        • ALLHAT Collaborative Research Group
        Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome.
        Arch Intern Med. 2008; 168: 207-217
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • Cushman W.C.
        • Green L.A.
        • Izzo Jr, J.L.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • National Collaborating Centre for Chronic Conditions
        Hypertension: management in adults in primary care: pharmacological update.
        Royal College of Physicians, London2006
        • Mancia G.
        • De Backer G.
        • Dominiczak A.
        • Cifkova R.
        • Fagard R.
        • Germano G.
        • et al.
        2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.
        J Hypertens. 2007; 25: 1751-1762
        • Jamerson K.
        • Weber M.A.
        • Bakris G.L.
        • Dahlof B.
        • Pitt B.
        • Shi V.
        • et al.
        • ACCOMPLISH trial investigators
        Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
        N Engl J Med. 2008; 359: 2417-2428
        • Ernst M.E.
        • Carter B.L.
        • Basile J.N.
        All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective.
        J Clin Hypertens (Greenwich). 2009; 11: 5-10
        • Carter B.L.
        • Ernst M.E.
        • Cohen J.D.
        Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
        Hypertension. 2004; 43: 4-9
        • Ernst M.E.
        • Carter B.L.
        • Zheng S.
        • Grimm Jr, R.H.
        Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium.
        Am J Hypertens. 2010; 23: 440-446
        • Ernst M.E.
        • Carter B.L.
        • Goerdt C.J.
        • Steffensmeier J.J.G.
        • Phillips B.B.
        • Zimmerman M.B.
        • et al.
        Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
        Hypertension. 2006; 47: 352-358
        • Multiple Risk Factor Intervention Trial Research Group
        Multiple Risk Factor Intervention Trial.
        JAMA. 1982; 248: 1465-1477
        • Bartsch G.
        • Broste S.
        • Grandits G.
        • Grimm R.H.
        • Neaton J.D.
        • Svendsen K.H.
        Hydrochlorothiazide, chlorthalidone and mortality in the Multiple Risk Factor Intervention Trial.
        Circulation. 1984; 70: 1438
        • Multiple Risk Factor Intervention Trial Research Group
        Mortality after 10½ years for hypertensive participants in the Multiple Risk Factor Intervention Trial.
        Circulation. 1990; 82: 1616-1628
        • Wing L.M.
        • Reid C.M.
        • Ryan P.
        • Beilin L.J.
        • Brown M.A.
        • Jennings G.L.
        • et al.
        A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly.
        N Engl J Med. 2003; 348: 583-592
        • Sica D.A.
        Chlorthalidone.
        Hypertension. 2006; 47: 321-322
        • Elliott W.J.
        • Grimm Jr, R.H.
        Using diuretics in practice—one opinion.
        J Clin Hypertens (Greenwich). 2008; 10: 856-862
        • Taler S.J.
        Should chlorthalidone be the diuretic of choice for antihypertensive therapy?.
        Curr Hypertens Rep. 2008; 10: 293-297
        • Kaplan N.M.
        The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide.
        Hypertension. 2009; 54: 951-953
        • Ernst M.E.
        • Lund B.C.
        Renewed interest in chlorthalidone: evidence from the Veterans Health Administration.
        J Clin Hypertens. 2010; 12: 927-934
        • Kurtz T.W.
        Chlorthalidone: don't call it “thiazide-like” anymore.
        Hypertension. 2010; 56: 335-337
        • Woodman R.
        • Brown C.
        • Lockette W.
        Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis.
        Hypertension. 2010; 56: 463-470
        • Temperini C.
        • Cecchi A.
        • Scozzafava A.
        • Supuran C.T.
        Carbonic anhydrase inhibitors: sulfonamide diuretics revisited—old leads for new applications?.
        Org Biomol Chem. 2008; 6: 2499-2506
        • Knauf H.
        • Mutschler E.
        Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure.
        J Cardiovasc Pharmacol. 1995; 26: 394-400
        • Dussol B.
        • Moussi-Frances J.
        • Morange S.
        • Somma-Delpero C.
        • Mundler O.
        • Berland Y.
        A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.
        Nephrol Dial Transplant. 2005; 20: 349-353
        • Rahman M.
        • Pressel S.
        • Davis B.R.
        • Nwachuku C.
        • Wright Jr, J.T.
        • Whelton P.K.
        • et al.
        • ALLHAT Collaborative Research Group
        Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic.
        Arch Intern Med. 2005; 165: 936-946
        • Rahman M.
        • Pressel S.
        • Davis B.R.
        • Nwachuku C.
        • Wright Jr, J.T.
        • Whelton P.K.
        • et al.
        • ALLHAT Collaborative Research Group
        Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
        Ann Intern Med. 2006; 144: 172-180
        • Broekhuysen J.
        • Deger F.
        • Douchamps J.
        • Ducarne H.
        • Herchuelz A.
        Torasemide, a new potent diuretic.
        Eur J Clin Pharmacol. 1986; 31: 29-34
        • Bomback A.S.
        • Kshirsagar A.V.
        • Amamoo M.A.
        • Klemmer P.J.
        Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
        Am J Kidney Dis. 2008; 51: 199-211
        • Navaneethan S.D.
        • Nigwekar S.U.
        • Sehgal A.R.
        • Strippoli G.F.
        Aldosterone antagonists for preventing the progression of chronic kidney disease.
        Cochrane Database Syst Rev. 2009; 3 (CD007004)
        • Ellison D.H.
        Diuretic resistance: physiology and therapeutics.
        Sem Nephrol. 1999; 19: 581-597
        • Ram C.V.
        • Garrett B.N.
        • Kaplan N.M.
        Moderate sodium restriction and various diuretics in the treatment of hypertension.
        Arch Intern Med. 1981; 141: 1015-1019
        • Sarafidis P.A.
        • Georgianos P.I.
        • Lasaridis A.N.
        Diuretics in clinical practice.
        Expert Opin Drug Saf. 2010; 9: 259-273
        • Savage P.J.
        • Pressel S.L.
        • Curb J.D.
        • Schron E.B.
        • Applegate W.B.
        • Black H.R.
        • et al.
        Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program.
        Arch Intern Med. 1998; 158: 741-751
        • Barzilay J.I.
        • Davis B.R.
        • Cutler J.A.
        • Pressel S.L.
        • Whelton P.K.
        • Basile J.
        • et al.
        • ALLHAT Collaborative Research Group
        Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment.
        Arch Intern Med. 2006; 166: 2191-2201
        • Hunter D.J.
        • York M.
        • Chaisson C.E.
        • Woods R.
        • Niu J.
        • Zhang Y.
        Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.
        J Rheumatol. 2006; 33: 1341-1345
        • Strom B.L.
        • Schinnar R.
        • Apter A.J.
        • Margolis D.J.
        • Lautenbach E.
        • Hennessy S.
        • et al.
        Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.
        N Engl J Med. 2003; 349: 1628-1635